Emerging studies suggest this peptide, a dual agonist targeting both incretin and glucose-dependent insulinotropic polypeptide , may represent a promising step forward for body treatment. Preliminary human tests have shown substantial losses in abdominal fat , potentially exceeding other obesity treatments. However , additional assessment is needed